IW-1701

DRUG3 trials

Sponsors

Cyclerion Therapeutics

Conditions

HealthySickle Cell Disease

Phase 1

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

CompletedNCT02572349

Cyclerion TherapeuticsHealthy

Start: 2015-10-31End: 2015-12-31Updated: 2019-04-03

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

CompletedNCT02792998

Cyclerion TherapeuticsHealthy

Start: 2016-05-31End: 2016-11-30Updated: 2019-04-03

Phase 2

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

CompletedNCT03285178

Cyclerion TherapeuticsSickle Cell Disease

Start: 2017-12-22End: 2020-07-22Updated: 2023-07-21

Related Papers

The Effect of the Soluble Guanylyl Cyclase Stimulator Olinciguat on ƴ-Globin Gene Induction in K562 Cells

Blood2018-11-295 citations